key: cord-0848398-rv9v3ihg
authors: Stern, Rebecca A.; Al-Hemoud, Ali; Alahmad, Barrak; Koutrakis, Petros
title: Levels and Particle Size Distribution of Airborne SARS-CoV-2 at a Healthcare Facility in Kuwait
date: 2021-03-27
journal: Sci Total Environ
DOI: 10.1016/j.scitotenv.2021.146799
sha: e2acdbc5eba65a0b6df879203a67055586f879ee
doc_id: 848398
cord_uid: rv9v3ihg

The Coronavirus Disease 2019 (COVID-19) pandemic spread rapidly despite extraordinary screening and social distancing measures. Such rapid spread was due in part to the fact that the disease transmission, particularly via airborne spread, is poorly understood. Characterizing the airborne size distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential to understanding the risk of airborne transmission. We collected size-fractionated (≤2.5, 2.5-10, and ≥10 μm) samples using a cascade impactor at more than 30 locations inside and outside Jaber Hospital and the nearby Temporary Quarantine Facility in Kuwait from April to July 2020. We hypothesized that airborne SARS-CoV-2 would be present in all size fractions, including fine particles, and in a size distribution that differed by sampling location. We found 6% of the samples (13 out of 210) were positive for SARS-CoV-2 RNA. Concentrations ranged from 3 to 25 copies/m3. The size distribution of particle-associated SARS-CoV-2 was different for each location. Large (≥10 μm) particles with the virus were found in symptomatic patient rooms. Fine (≤2.5 μm) particle-associated SARS-CoV-2 was detected in rooms with intubated patients and outside the hospital entrance gates. Coarse (2.5-10 μm) virus-laden particles were present in all locations with positive samples. This is the most comprehensive study to date on size-fractionated airborne SARS-CoV-2 RNA. Our findings support location-specific precautions that mitigate the spread of particles including fine particulate matter over distances greater than 1 meter, including in locations outside the hospital.

Coronavirus Disease 2019 (COVID-19) spread rapidly around the world and challenged existing conceptions of disease transmission and prevention. 1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, was recently shown to remain viable in aerosols for 1.5 to 16 hours. 2, 3, 4 However, little is known about the size distribution of SARS-CoV-2 in indoor and outdoor air. This property of airborne SARS-CoV-2 is essential for predicting the spread of the disease.

Of particular concern, healthcare workers are at increased risk of occupational exposure to SARS-CoV-2. The U.S. Occupational Safety and Health Administration (OSHA) now recommends airborne precautions to protect healthcare workers with exposure to the virus. 5 While many hospitals around the world grapple with risk reduction strategies for frontline healthcare workers during the pandemic, there is also notable nosocomial COVID-19 transmission among inpatients. 6 Infection control strategies aim to curb such risks as well as improve the resilience of healthcare workers. It becomes imperative to understand the role of air particles that serve as vectors for SARS-CoV-2 in the hospital workplace in which conventional infection control strategies may fall short.

Traditionally, the medical community has relied on the dichotomy of droplet (large particles that affect recipients) and aerosol (smaller particles that remain airborne for longer periods and can be inhaled) to characterize host-to-host transmission mechanisms. This is essential for risk management and allocation of resources to J o u r n a l P r e -p r o o f Journal Pre-proof control respiratory infectious diseases. 7 In the COVID-19 pandemic, authorities stressed the importance of droplet transmission. However, breathing, talking, singing, and coughing release particles of a continuum of sizes. 8 Even larger particles that are produced from processes such as coughing 9 and sneezing 10 may dry out and become smaller. 11 Evidence suggests that smaller aerosols, including those generated by speaking, may be a vector for COVID-19. [12] [13] [14] [15] These smaller particles have significant health impacts, as they are capable of penetrating deeper into the lungs. In other respiratory diseases, pathogens on smaller particles require fewer microorganisms to cause an infection than those on larger particles. [16] [17] [18] A wealth of air pollution studies have shown that fine particulate matter (≤2.5 µm) remains airborne for several hours before being removed from the air by gravitational settling. 11, [19] [20] [21] [22] As a result, smaller particles can travel farther than 1 meter, which is the social distancing space currently recommended by the World Health Organization, 23 In this over two-month-long study, we present the most comprehensive COVID-19 air-sampling program in healthcare workplaces to date, with 210 individually analyzed size-fractionated samples. We collected simultaneous air samples in three different size fractions at over 30 hospital locations including intensive care units (ICU), nurses' workstations, the rooms of inpatients with and without symptoms, observation rooms (transitional treatment units in the emergency department where patients are continuously evaluated before the decision to admit or discharge), locker rooms, bathrooms, a lobby, waiting areas, patient hallways, testing rooms, and outside hospital entrances. We examined the size distribution of SARS-CoV-2 in airborne particles in three distinct size fractions: fine particles ≤2.5 µm (which are small enough to remain suspended in the air and penetrate deep into the airways and directly into the bloodstream), coarse particles 2.5-10 µm (which are inhalable but do not penetrate deeply into the lungs), and large particles ≥10 µm (which have relatively high settling velocities and travel shorter distances before settling out of the air). We hypothesize that SARS-CoV-2 RNA would be present in indoor air in different size fractions, including fine particulate matter, and that the aerodynamic size distribution would depend on the sampling location. were admitted to the hospital. Asymptomatic patients were discharged from the hospital only when they repeatedly tested negative on nasopharyngeal swabs.

J o u r n a l P r e -p r o o f

We conducted two sampling campaigns. The first campaign lasted from April 30 to May 20, 2020. The second campaign occurred between June 24 and July 10, 2020. The first campaign was only conducted at Jaber Hospital (inside and outside). Locations in the first campaign included ambient-pressure ICUs, inside rooms of symptomatic and asymptomatic patients with one to four beds, nearby nurses" workstations, inside a nurses" locker room, and at three different outside gates (Table S1 ). The second campaign included Jaber hospital (inside and outside), as well as locations inside and outside the TQF. Jaber Hospital locations during the second campaign included negative pressure ICUs, ambient pressure ICUs, bathrooms (2 meters away from the toilet), observation rooms where patients waited to be evaluated, and an outdoor gate.

Locations at the TQF during the second campaign included a reception waiting area, COVID-19 swab testing waiting area, patient area hallway, main entrance gate, and swab testing area exit (Table S2) . We collected 84 samples in the first campaign from Jaber Hospital locations, 66 samples from the second campaign from Jaber Hospital locations, and 60 samples from the second campaign at the TQF (210 samples). We used a blank cascade for each collection period (36 total) and processed them simultaneously with the corresponding samples for that given period.

We used custom-designed Harvard Micro-Environmental Cascade Impactors 29 

We collected 210 samples during the study period. Out of the Jaber Hospital samples (150 samples total), 13 were positive (Table 1) (Table   S4 ). All blanks were negative for SARS-CoV-2 RNA.

The fraction of positive samples was greatest for the symptomatic patient rooms (6 out of 24 samples or 25%) (Table S5 ). The ambient-pressure ICU and outside the hospital 

The results comprise the largest dataset on size-fractionated airborne SARS-CoV-2 RNA. We collected 210 samples at Kuwait"s designated COVID-19 inpatient state-ofthe-art hospital and quarantine facility. We found positive samples in all three-size fractions (fine ≤2.5 µm, coarse 2.5-10 µm, and large ≥10 µm). We confirmed our hypothesis, finding positives samples in the fine size fraction and in a pattern indicating location-specific size distributions.

A key finding is that the size distribution of particle-associated SARS-CoV-2 was dependent on the location where the particles were collected. Samples collected in symptomatic patient rooms were associated with larger particles, which may be because patients were not required to wear their masks at all times in their rooms.

Symptomatic patients were also more likely to cough and sneeze, and both of these behaviors generate larger particles than speaking and breathing. 30 By contrast, all samples collected in the asymptomatic patient rooms were negative. This could be because asymptomatic patients had a longer hospital stay than symptomatic patients, and therefore may have become less infectious over time. 31 µm, which is smaller than the large size fraction tested. 32 This size distribution agrees with our finding of SARS-CoV-2 RNA in the fine size fraction in the intubated patient rooms. It reinforces the importance of airborne personal protective gear for ICU healthcare workers that limits small particle exposure, especially for physicians and nurses attending to intubated patients. The current emphasis on "droplet precautions"

during patient intubation and extubation may be leading to emphasis on large droplet routes and oversight of smaller aerosol precautions that could prevent spread. 33, 34 None of the negative pressure ICU sampling locations yielded positive results. The negative pressure precautions appeared to be effective at keeping airborne concentrations of the virus low or zero. [35] [36] [37] Engineering controls such as negative pressure could be challenging in some hospital environments that are already

overwhelmed; yet, we show that these conditions appear to be effective. This study has some limitations. First, the concentrations estimated in this study were time-weighted averages over 48-hour sampling periods, and it is possible that the emissions of the virus into the air occurred in discrete bursts rather than continuously over the entire sampling period. Thus, someone exposed may have received a higher "dose" in the air than those implied based on the measured concentrations. Additionally, we were not able to obtain data on air exchange rates in the indoor sampling locations and therefore we could not assess the effects of ventilation on the presence of airborne SARS-CoV-2 or the number of viral copies in positive samples. The infectious dose of SARS-CoV-2 is still unknown. It is possible that it is similar to that of SARS-CoV-1, 53 which was estimated to require 280 viral particles to cause illness in 50% of people. 54 Further, given the sampling method, the present study did not measure viability of the 

Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity

Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions

Healthcare Workers and Employers. COVID-19 Control and Prevention

Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center

Infection Prevention and Control of Epidemic-and Pandemic-Prone Acute Respiratory Infections in Health Care

Modality of human expired aerosol size distributions

The size and concentration of droplets generated by coughing in human subjects

Violent expiratory events: on coughing and sneezing

On air-borne infection. Study II. Droplets and droplet nuclei

It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19)

Airborne transmission of SARS-CoV-2: The world should face the reality

A systematic review of possible airborne transmission of the COVID-19 virus (SARS-CoV-2) in the indoor air environment

The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission

Particle size and pathogenicity in the respiratory tract

Toward understanding the risk of secondary airborne infection: emission of respirable pathogens

Review of aerosol transmission of influenza A virus

Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles

Influence of natural ventilation rate on indoor PM2. 5 deposition

A mathematical model for predicting indoor PM2. 5 concentration under different ventilation methods in residential buildings

Airborne or Droplet Precautions for Health Workers Treating Coronavirus Disease

Detection of air and surface contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in hospital rooms of infected patients

Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. medRxiv

The infectious nature of patientgenerated SARS-CoV-2 aerosol

Characterization of hospital airborne SARS-CoV-2

Development and Laboratory Performance Evaluation of a Personal Cascade Impactor

The size distribution of droplets in the exhaled breath of healthy human subjects

Virological assessment of hospitalized patients with COVID-2019

Particle size concentration distribution and influences on exhaled breath particles in mechanically ventilated patients

COVID-19 and risks posed to personnel during endotracheal intubation

Expert Recommendations for Tracheal Intubation in Critically III Patients with Noval Coronavirus Disease

Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement

Health Care Infection Control Practices Advisory Committee 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings

Rapid expansion of temporary, reliable airborne-infection isolation rooms with negative air machines for critical COVID-19 patients

Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19)

Indoor transmission of SARS-CoV-2

Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care

Toilets dominate environmental detection of SARS-CoV-2 virus in a hospital

Hospital indoor air quality monitoring for the detection of SARS-CoV-2 (COVID-19) virus

Environmental and Aerosolized Severe Acute Respiratory Syndrome Coronavirus 2 Among Hospitalized Coronavirus Disease

SARS-CoV-2 RNA detection in the air and on surfaces in the COVID-19

Aerosol and environmental surface monitoring for SARS-CoV-2 RNA in a designated hospital for severe COVID-19 patients

Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from a Symptomatic Patient

Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19)

A field indoor air measurement of SARS-CoV-2 patient rooms of the largest hospital in Iran

Investigation of hospital indoor air quality for the presence of SARS-Cov-2

Coronavirus Disease 2019 Patients in Earlier Stages Exhaled Millions of Severe Acute Respiratory Syndrome Coronavirus 2 Per Hour

Estimation of airborne viral emission: Quanta emission rate of SARS-CoV-2 for infection risk assessment

Is there an airborne component to the transmission of COVID-19?: a quantitative analysis study

Development of a doseresponse model for SARS coronavirus

Airborne SARS-CoV-2 was found in many indoor and outdoor locations in Jaber Hospital. 2. Viral concentrations were highest in symptomatic patient rooms

SARS-CoV-2 RNA was detected in smaller particles (<10 µm) in ICUs and outside. 5. Fine particles with SARS-CoV-2 suggests that the virus can travel farther than 1m